Senior Civil Service pay: the FDA's submission to the Senior Salaries Review Body

February 8, 2018

FDA Assistant General Secretary Naomi Cooke highlights the key points from our submission to the body that reviews Senior Civil Service (SCS) pay - and warns that the government's proposals are "too little in terms of reform and too meagre in terms of funding"


The FDA gave oral evidence to the Senior Salaries Review Body (SSRB) on 30 January following our submission of written evidence earlier this year. Our written evidence relies heavily on the results of the SCS Pay survey conducted in December, and we would like to thank everyone who participated in that survey for taking the time to do so.
Unusually, the Government published their evidence ahead of the SSRB's oral evidence sessions, and that evidence is available to read here. The FDA’s own written evidence - available to read below - was therefore able to respond to the proposals in the Government's evidence.
Our submission, which you can read here, makes the case for fundamental reform to the SCS pay framework and performance management system, as well as a real-terms pay increase for all members of the SCS. We also take the opportunity to critique the government's proposals which, as highlighted previously, we do not believe show the necessary urgency or sincerity.
The government makes a number of proposals for reform, but its key proposals are:

  • To shorten pay ranges and determine those ranges by profession with the bulk of SCS 1 civil servants intended to be on a minimum of £70,000 by 2020-1;
  • To restrict pay on promotion or level transfer for internal applicants within the SCS;
  • To restrict awards for those above the intended new pay range or those not classed as ‘high performers’

There are some positive moves on flexibility with non-consolidated awards, but fundamentally what is proposed is too little in terms of reform and too meagre in terms of funding. The only money seemingly available is the 1% already allocated before the cap was ‘lifted’ as well as the minimal amounts 'saved' by taking from those seeking to develop their careers by moving around the SCS.
We reflect these points in our evidence and we have urged the SSRB to recognise our concerns in their recommendations. The SSRB is due to publish their report in the coming months.

As ever, If you have any comments or views on any issues affecting the SCS, please get in touch with us at

FDA and Prospect Written Evidence to the SSRB January 2018 by FDAunion on Scribd


The FDA's submission to the SSRB forms part of our ongoing campaign for a fair and fully-funded pay rise for all public sector staff. You can find out more and see how pay policy has affected you at